Cidara Therapeutics Receives FDA Fast Track Designation For CD388, A Novel Drug-Fc Conjugate Targeting Influenza A And B
Portfolio Pulse from Bill Haddad
Cidara Therapeutics has received FDA Fast Track designation for its novel drug-Fc conjugate, CD388, targeting Influenza A and B. This designation will expedite the development and review process for the drug.
June 22, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cidara Therapeutics' stock may see a positive impact as the company receives FDA Fast Track designation for its novel drug, CD388, targeting Influenza A and B.
The FDA Fast Track designation for CD388 is a significant milestone for Cidara Therapeutics, as it will expedite the development and review process for the drug. This news is likely to be viewed positively by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100